36. Mocarska A., Starosławska E., Kieszko D. et al. Usefulness of magnetic resonance in evaluation of cervical cancer
progression // Ginekol. Pol. 2012, Feb. Vol. 83. N. 2. P. 122-127.
37. Monteil J., Maubon A., Leobon S. et al. Lymph node assessment with (18)F-FDG-PET and MRI in uterine cervical cancer //
Anticancer Res. 2011, Nov. Vol. 31. N. 11. P. 3865-3871.
38. Morgan R.J., Armstrong D.K., Alvarez R.D. et al. Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in
Oncology // J of the National Comprehensive Cancer Network: JNCCN. 2016. Vol. 14. N. 9. P. 1134-1163.
39. Mubarak F., Akhtar M.W., Gul-e-Khanda et al. Staging of endometrial carcinoma by MRI: correlation with surgery and
histopathology // J Pak Med Assoc. 2009, Sep. Vol. 59. N. 9. Р. 622-625.
40. Punwani S. Contrast enhanced MR imaging of female pelvic cancers: established methods and emerging applications // Eur J
Radiol. 2011, Apr. Vol. 78. N. 1. P. 2-11.
41. Sala E., Rockall A., Rangarajan D. et al. The role of dynamic contrast-enhanced and diffusion weighted magnetic resonance
imaging in the female pelvis // Eur J Radiol. 2010, Dec. Vol. 76. N. 3. P. 367-85.
42. Qin Y., Peng Z., Lou J. et al. Discrepancies between clinical staging and pathological findings of operable cervical carcinoma
with stage IB-IIB: a retrospective analysis of 818 patients // Aust NZJ Obstet Gynaecol. 2009. N. 49. P. 542-544.
43. Quinn M., Benedet J., Odicino F. et al. Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment
in Gynecological Cancer // Int J Gynecol Obstet. 2006. Vol. 95. Suppl. 1. P. 43-103, 944. Eur Radiol. 2017. Vol. 27.
P. 938-945.
44. Young P., Daniel B., Sommer G. et al. Intravaginal gel for staging of female pelvic cancers-preliminary report of safety,